Superworth

Crescent Biopharma price to book ratio CBIO

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
2.9×
10-year median
1.8×
Against its 10-year history
73rd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 10.4×
Peer median
1.9×

Crescent Biopharma's price to book ratio is 2.9× as of Oct 23, 2026.

That is above its ten-year median of 1.8×, higher than on 73% of days in the last ten years.

Over that time it ranged from 0.4× in May 2022 to 10.4× in Jun 2017.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.9×1.1×4.8×
20251.5×1.1×4.7×
20241.3×0.5×5.0×
20233.3×1.3×3.8×
20223.3×0.4×3.3×
20210.8×0.8×1.4×
20201.3×0.6×1.4×
20191.5×0.8×2.8×
20181.8×1.8×7.9×
20175.3×2.6×10.4×
20163.4×1.5×5.0×
20152.2×1.9×3.7×
20142.5×1.9×3.2×

Against its peers

Companies in Drug Manufacturers - General nearest Crescent Biopharma's size, closest first, today.

CompanyPrice to book ratio
CBIOCrescent Biopharma2.9×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
NATRNatures Sunshine Products1.3×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Crescent Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.